VTVT vTv Therapeutics

vTv Therapeutics to Present at Two Upcoming Annual Investor Conferences

HIGH POINT, N.C.--(BUSINESS WIRE)--

vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, among other therapeutic areas, today announced that company management will present a corporate overview at two upcoming investor conferences.

Presentation Details:

ROTH Capital Partners 29th Annual Growth Stock Conference

  • Location: Dana Point, California
  • Presentation Date: Tuesday, March 14, 2017
  • Presentation Time: 7:30 am PT

Needham & Co. 16th Annual Healthcare Conference

  • Location: New York, New York
  • Presentation Date: Tuesday, April 4, 2017
  • Presentation Time: 4:20 pm ET

Live webcasts of the presentations can be accessed on the News & Events section of the website. The webcasts will be archived for 30 days following the presentations on the Company’s website at www.vtvtherapeutics.com.

About vTv Therapeutics

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and Type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.

EN
10/03/2017

Underlying

VTVTvTv Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on vTv Therapeutics

 PRESS RELEASE
Free
VTVT vTv Therapeutic...

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Pro...

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update •   First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026 •   Cadisegliatin intellectual property portfolio expanded •   Leadership team strengthened HIGH POINT, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being...

August 12, 2025 1 EN
 PRESS RELEASE
Free
VTVT vTv Therapeutic...

vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegl...

vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin HIGH POINT, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application directed to compositions of matter of crystalline forms of salts and co-crystals of cad...

August 11, 2025 1 EN
 PRESS RELEASE
Free
VTVT vTv Therapeutic...

vTv Therapeutics Announces First Study Participant Randomized in CATT1...

vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes Topline results from CATT1 Phase 3 trial expected in second half of 2026 HIGH POINT, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced the first study participant has been randomized in the Company’s CATT1 Phase 3 trial investigating cadisegliatin as an adjunctive treatment to insulin in adults with t...

August 7, 2025 1 EN
 PRESS RELEASE
Free
VTVT vTv Therapeutic...

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Seri...

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series HIGH POINT, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the H.C. Wainwright “HCW@Home” Series, being held virtually on Thursday, June 12, 2025. Conference details are as follows: H.C. Wainwright “HCW@Home with vTv Therape...

June 11, 2025 1 EN
 PRESS RELEASE
Free
VTVT vTv Therapeutic...

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial ...

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin HIGH POINT, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced the appointment of Michael Tung, M.D., MBA as Executive Vice President and Chief Financial Officer, effective immediately. Dr. Tung joins the Company with 20 years of diversified finance, corporate strategy, investor relations, and business development experience in the biopharmaceutical indu...

May 19, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch